Switch theme
Sign up to access all valuation multiples
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
1990
77
LTM Revenue $10.0M
LTM EBITDA -$22.0M
$56.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lineage Cell Therapeutics has a last 12-month revenue of $10.0M and a last 12-month EBITDA of -$22.0M.
In the most recent fiscal year, Lineage Cell Therapeutics achieved revenue of $9.5M and an EBITDA of -$20.9M.
Lineage Cell Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lineage Cell Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $8.9M | $9.5M | XXX | XXX | XXX |
| Gross Profit | $14.0M | $8.3M | XXX | XXX | XXX |
| Gross Margin | 156% | 87% | XXX | XXX | XXX |
| EBITDA | -$24.0M | -$20.9M | XXX | XXX | XXX |
| EBITDA Margin | -269% | -220% | XXX | XXX | XXX |
| Net Profit | -$26.3M | -$21.5M | XXX | XXX | XXX |
| Net Margin | -294% | -226% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Lineage Cell Therapeutics's stock price is $0.
Lineage Cell Therapeutics has current market cap of $101M, and EV of $56.2M.
See Lineage Cell Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $56.2M | $101M | XXX | XXX | XXX | XXX | $-0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Lineage Cell Therapeutics has market cap of $101M and EV of $56.2M.
Lineage Cell Therapeutics's trades at 5.6x LTM EV/Revenue multiple, and -2.6x LTM EBITDA.
Analysts estimate Lineage Cell Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lineage Cell Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $56.2M | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | XXX | XXX |
| P/E | -5.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLineage Cell Therapeutics's NTM/LTM revenue growth is 59%
Lineage Cell Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Lineage Cell Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lineage Cell Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lineage Cell Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -220% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -160% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 191% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 131% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 323% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| Orthocell | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lineage Cell Therapeutics acquired XXX companies to date.
Last acquisition by Lineage Cell Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Lineage Cell Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Lineage Cell Therapeutics founded? | Lineage Cell Therapeutics was founded in 1990. |
| Where is Lineage Cell Therapeutics headquartered? | Lineage Cell Therapeutics is headquartered in United States of America. |
| How many employees does Lineage Cell Therapeutics have? | As of today, Lineage Cell Therapeutics has 77 employees. |
| Who is the CEO of Lineage Cell Therapeutics? | Lineage Cell Therapeutics's CEO is Mr. Brian M. Culley, M.S.. |
| Is Lineage Cell Therapeutics publicy listed? | Yes, Lineage Cell Therapeutics is a public company listed on ASE. |
| What is the stock symbol of Lineage Cell Therapeutics? | Lineage Cell Therapeutics trades under LCTX ticker. |
| When did Lineage Cell Therapeutics go public? | Lineage Cell Therapeutics went public in 1992. |
| Who are competitors of Lineage Cell Therapeutics? | Similar companies to Lineage Cell Therapeutics include e.g. Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics, Mesoblast. |
| What is the current market cap of Lineage Cell Therapeutics? | Lineage Cell Therapeutics's current market cap is $101M |
| What is the current revenue of Lineage Cell Therapeutics? | Lineage Cell Therapeutics's last 12-month revenue is $10.0M. |
| What is the current EBITDA of Lineage Cell Therapeutics? | Lineage Cell Therapeutics's last 12-month EBITDA is -$22.0M. |
| What is the current EV/Revenue multiple of Lineage Cell Therapeutics? | Current revenue multiple of Lineage Cell Therapeutics is 5.6x. |
| What is the current EV/EBITDA multiple of Lineage Cell Therapeutics? | Current EBITDA multiple of Lineage Cell Therapeutics is -2.6x. |
| What is the current revenue growth of Lineage Cell Therapeutics? | Lineage Cell Therapeutics revenue growth between 2023 and 2024 was 6%. |
| Is Lineage Cell Therapeutics profitable? | Yes, Lineage Cell Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
